Is a complete IBRX research report available?

No complete published report is available for ImmunityBio, Inc. (IBRX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · USD

$7.10

-0.30 (-4.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-27 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IBRX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	7.4B
Revenue (ttm)	141M
Net income (ttm)	-854.5M
EPS (ttm)	-$0.89
Shares out	1B
Volume	8,524,632
Beta	0.08
Price target	$13.0	+83.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 141M
Net income (ttm): -854.5M
EPS (ttm): -$0.89
Market cap: 7.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IBRX indicators

Market & fundamental data

Available fields

208

Groups with data

Currency

USD

Showing 208 of 208 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001326110
Company name	ImmunityBio, Inc.
Country	United States
Country code	US
Cusip	45256X103
Employees	691
Employees Change	11%
Employees Change Percent	1.62
Enterprise value	$8.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US45256X1037
Last refreshed	2026-07-27
Market cap	$7.4B
Market cap category	Mid-Cap
Price	$7.1
Price currency	USD
Rev Per Employee	204,018.81x
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2836
Symbol	IBRX
Website	https://immunitybio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.49%
EV Sales Forward	34.24x
EV/Sales	58.02x
FCF yield	-4.02%
P/S ratio	52.75x
PS Forward	31.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-185.41%
EBITDA Margin	-174.01%
Gross margin	99.34%
Gross Profit	$140M
Gross Profit Growth	349.38%
Gross Profit Growth Q	167.14%
Gross Profit Growth3 Y	520.57%
Gross Profit Growth5 Y	199.72%
Net Income	$-854.5M
Net Income Growth Years	2%
Pretax Margin	-606.12%
Profit Per Employee	$-1.2M
ROA	-34.38
Roa5y	-49.39
ROCE	-45.17
ROIC	-67.01

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	137.6%
Cagr3y	36.19%
Cagr5y	-8.06%
EPS Growth Years	2
Revenue Growth	351.53x
Revenue Growth Q	167.64x
Revenue Growth Quarters	8x
Revenue Growth Years	3x
Revenue Growth3 Y	521.94x
Revenue Growth5 Y	200.12x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.3
Assets	$646.6M
Cash	$380.9M
Current Assets	$453M
Current Liabilities	$68M
Debt	$1.1B
Equity	$-869.1M
Interest Coverage	-2.33
Liabilities	$1.5B
Long Term Assets	$193.7M
Long Term Liabilities	$1.4B
Net Cash	$-743.7M
Net Cash By Market Cap	$-10
Tangible Book Value	$-882.9M
Tangible Book Value Per Share	$-0.84
WACC	5.1

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.67
Inventory Turnover	0.21
Net Working Capital	$12.7M
Quick ratio	6.24
Working Capital	$385M
Working Capital Turnover	$0.63

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-29.76%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	137.46%
200-day SMA	5.8
3Y total return	152.67%
50-day SMA	7.77
50-day SMA vs 200-day SMA	50over200
5Y total return	-34.32%
All Time High	40.83
All Time High Change	-82.61%
All Time High Date	2021-03-11
All Time Low	1.21
All Time Low Change	486.78%
All Time Low Date	2023-03-15
ATR	0.52
Beta	0.08
Beta1y	1.65
Beta2y	1.83
Ch YTD	258.6
High	7.45
High52	12.43
High52 Date	2026-02-25
High52ch	-42.88%
Low	7.06
Low52	1.95
Low52 Date	2025-12-31
Low52ch	264.1%
Ma50ch	-8.62%
Premarket Change Percent	0.54
Premarket Price	$7.44
Premarket Volume	28,380
Price vs 200-day SMA	22.39%
RSI	39.87
RSI Monthly	55.76
RSI Weekly	51.89
Sharpe ratio	1.27x
Sortino ratio	2.49
Total Return	-29.76%
Tr YTD	258.6
Tr1m	-3.01%
Tr1w	-7.55%
Tr3m	-13.31%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	2
Analyst Price Target Top	$13.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.08
Earnings Revenue Estimate	49,047,336x
Earnings Revenue Estimate Growth	85.61x
Operating Income	$-261.4M
Operating margin	-185.4
Price target	$13
Price Target Change	$83.1
Price Target Change Top	$90.14

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	394,156,849%
Float Percent	37.63%
Net Borrowing	75,904,000
Shares Insiders	28.23%
Shares Institutions	17.8%
Shares Out	1,047,353,977
Shares Qo Q	3.76%
Shares Yo Y	29.76%
Short Float	33.45%
Short Ratio	9.91
Short Shares	12.59

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-334.3M
Average Volume	11,771,630.45x
Bv Per Share	-0.83
CAPEX	$-4.5M
Ch1m	-3.01
Ch1w	-7.55
Ch1y	137.5
Ch3m	-13.31
Ch3y	152.7
Ch5y	-34.32
Ch6m	10.08
Change	-4.05%
Change From Open	-4.05
Close	7.4
Days Gap	0
Depreciation Amortization	15,976,000
Dollar Volume	60,524,887.2
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-261.4M
EBITDA	$-245.3M
EPS	$-0.89
F Score	3
FCF	$-298.9M
FCF EV Yield	-3.65x
FCF Per Share	$-0.29
Financing CF	625,149,000
Fiscal Year End	December
Founded	2,014
Goodwill	910,000
Income Tax	$108,000
Investing CF	-185,580,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-23
Ma150	6.97
Ma150ch	1.81%
Ma20	8.23
Ma20ch	-13.7%
Net CF	145,326,000
Next Earnings Date	2026-08-07
Open	7.4
Optionable	Yes
Position In Range	10.26
Post Close	7.1
Postmarket Change Percent	0.28
Postmarket Price	$7.12
Ppne	146,075,000
Pre Close	7.4
Price Date	2026-07-24
Relative Volume	0.72x
Revenue	140,977,000x
SBC By Revenue	25.14x
Share Based Comp	35,441,000
Tax By Revenue	0.08x
Tr6m	10.08%
Us State	California
Volume	8,524,632
Z Score	-8.48

ImmunityBio, Inc. (IBRX)

Coverage state: Market snapshot only — no published research

Generate the first IBRX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IBRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IBRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IBRX

Frequently asked questions